VanEck Associates’s Cantel Medical Corporation CMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-20,002
| Closed | -$1.6M | – | 1329 |
|
|
2021
Q1 | $1.6M | Buy |
20,002
+2,244
| +13% | +$175K | ﹤0.01% | 658 |
|
|
2020
Q4 | $1.4M | Sell |
17,758
-8,024
| -31% | -$471K | ﹤0.01% | 605 |
|
|
2020
Q3 | $1.13M | Sell |
25,782
-1,616
| -6% | -$79.6K | ﹤0.01% | 615 |
|
|
2020
Q2 | $1.21M | Sell |
27,398
-12,003
| -30% | -$448K | ﹤0.01% | 583 |
|
|
2020
Q1 | $1.41M | Buy |
39,401
+23,111
| +142% | +$1.31M | 0.01% | 511 |
|
|
2019
Q4 | $1.16M | Buy |
16,290
+885
| +6% | +$64.2K | ﹤0.01% | 615 |
|
|
2019
Q3 | $1.15M | Sell |
15,405
-1,023
| -6% | -$86.7K | 0.01% | 574 |
|
|
2019
Q2 | $1.32M | Buy |
16,428
+213
| +1% | +$15K | 0.01% | 536 |
|
|
2019
Q1 | $1.08M | Buy |
16,215
+5,336
| +49% | +$404K | 0.01% | 563 |
|
|
2018
Q4 | $810K | Buy |
10,879
+1,938
| +22% | +$160K | ﹤0.01% | 568 |
|
|
2018
Q3 | $823K | Buy |
8,941
+363
| +4% | +$34.6K | ﹤0.01% | 604 |
|
|
2018
Q2 | $844K | Buy |
8,578
+1,195
| +16% | +$134K | ﹤0.01% | 584 |
|
|
2018
Q1 | $823K | Buy |
7,383
+1,261
| +21% | +$141K | ﹤0.01% | 486 |
|
|
2017
Q4 | $630K | Sell |
6,122
-888
| -13% | -$88.5K | ﹤0.01% | 532 |
|
|
2017
Q3 | $660K | Sell |
7,010
-2,855
| -29% | -$225K | ﹤0.01% | 530 |
|
|
2017
Q2 | $769K | Buy |
9,865
+96
| +1% | +$7.21K | ﹤0.01% | 509 |
|
|
2017
Q1 | $782K | Buy |
9,769
+508
| +5% | +$40.4K | ﹤0.01% | 525 |
|
|
2016
Q4 | $729K | Buy |
9,261
+1,028
| +12% | +$79.9K | ﹤0.01% | 520 |
|
|
2016
Q3 | $642K | Sell |
8,233
-1,733
| -17% | -$126K | ﹤0.01% | 548 |
|
|
2016
Q2 | $685K | Buy |
9,966
+1,204
| +14% | +$83K | ﹤0.01% | 513 |
|
|
2016
Q1 | $625K | Sell |
8,762
-125
| -1% | -$7.85K | ﹤0.01% | 504 |
|
|
2015
Q4 | $552K | Sell |
8,887
-1,178
| -12% | -$71.9K | ﹤0.01% | 463 |
|
|
2015
Q3 | $571K | Sell |
10,065
-740
| -7% | -$39.2K | ﹤0.01% | 447 |
|
|
2015
Q2 | $580K | Sell |
10,805
-1,204
| -10% | -$58.6K | ﹤0.01% | 471 |
|
|
2015
Q1 | $570K | Buy |
12,009
+407
| +4% | +$18K | ﹤0.01% | 483 |
|
|
2014
Q4 | $502K | Sell |
11,602
-1,432
| -11% | -$58.5K | ﹤0.01% | 480 |
|
|
2014
Q3 | $448K | Sell |
13,034
-1,406
| -10% | -$49.7K | ﹤0.01% | 510 |
|
|
2014
Q2 | $529K | Buy |
14,440
+477
| +3% | +$16.2K | ﹤0.01% | 483 |
|
|
2014
Q1 | $471K | Sell |
13,963
-171
| -1% | -$5.64K | ﹤0.01% | 476 |
|
|
2013
Q4 | $479K | Sell |
14,134
-3,724
| -21% | -$129K | ﹤0.01% | 457 |
|
|
2013
Q3 | $569K | Sell |
17,858
-4,219
| -19% | -$112K | ﹤0.01% | 420 |
|
|
2013
Q2 | $498K | Buy |
+22,077
| New | +$478K | ﹤0.01% | 424 |
|
VanEck Associates's CMD Position: Q2 2021 in Review
VanEck Associates sold out of Cantel Medical Corporation (CMD) in Q2 2021, closing a stake of 20,002 shares — an estimated $1.6M sold.
VanEck Associates first reported a position in CMD in Q2 2013 and held it in 32 quarters. The position peaked at $1.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold CMD as of Q2 2021.
- VanEck Associates reported no remaining Cantel Medical Corporation position as of Q2 2021 after selling out during the quarter.
- VanEck Associates sold 20,002 Cantel Medical Corporation shares in Q2 2021, an estimated $1.6M.
- VanEck Associates first reported a position in Cantel Medical Corporation in Q2 2013 and held it in 32 quarters.
- VanEck Associates's Cantel Medical Corporation position peaked at $1.6M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q2 2021.
Based on VanEck Associates's 13F filing for Q2 2021, filed 10 Aug 2021.